The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma
June 5th 2013The immunomodulatory agent lenalidomide is now approved by the FDA to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Dabrafenib and Trametinib Both Approved for Advanced Melanoma
May 29th 2013The FDA approved both dabrafenib and trametinib for the treatment of patients with metastatic or unresectable melanoma, as well as a companion diagnostic to properly identify the patients exhibiting the mutations that are targeted by these agents.
FDA Approves Frontline Erlotinib With Novel Companion Diagnostic for Advanced NSCLC
May 14th 2013The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.
Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership
May 7th 2013OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.
ODAC Turns Down Chemosaturation System
May 2nd 2013Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.
PD-1 Targeted Antibody Lambrolizumab Receives FDA Breakthrough Designation
April 25th 2013Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.